Digital-Pathology-Today Magpie Communications

Today we are discussing how treatment decisions can be personalized through artificial intelligence and digital pathology. Our guest is Andre Esteva of Artera. Atera’s first product is in prostate cancer. We discuss how AI can improve upon the current state of the practice which largely relies on making decisions based on clinical nomograms.

We discuss the concepts prediction and prognosis and how both are incorporated into treatment decisions; what goes into developing and validating AI based algorithms in digital pathology and the importance of validating these algorithms in the appropriate studies specifically randomized clinical trials.

There is one huge advantage of AI based digital pathology tools over genomics and molecular tools. Image based tools can be performed instantaneously rather than waiting days to weeks.

Andre Esteva is a researcher and entrepreneur in medical artificial intelligence. He currently serves as CEO of Artera and was previously Head of Medical AI at Salesforce Research. He has worked at Google Research, Sandia National Labs, GE Healthcare, and has founded four companies.

His research efforts have largely focused on medical AI diagnostics and precision medicine. His publications have made the covers of Nature and Nature Medicine, and have been featured in Cell, The Lancet, NeurIPS, and similar venues. These works have been widely covered by the WSJ, Fortune, BBC, The Economist, and hundreds of other news outlets.

What is pathology 3.0?

We are at an inflection point. The demand on pathologists in laboratory medicine is greater than ever. Demographics and healthcare needs of the population are shifting. New technologies such as digital pathology and molecular diagnostics are now a reality. The rules of the game are changing. There are times in any industry where massive change is inevitable and there is great opportunity to grow. And for this, we need a new mindset.

Pathology 1.0 was transactional. Clinicians would send in the specimen we would send the results. Passive and fragmented. Not responsive.

Pathology 2.0 involved consolidation, taking advantage of economies of scale and scope. But still transactional and fragmented.

Pathology 3.0 is connected, intelligent and evolving. Pathologists can add unique value and build on previous waves of consolidation. It transcends the boundaries of disciplines and organizational silos. It integrates new technologies and is interactive.

Branko Perunovic is Chief Medical Officer at Black Country Pathology Service, where he leads the pathology consolidation and the delivery of high-quality and innovative pathology services.

His journey has taken him through various aspects of healthcare, including transforming pathology services, consolidating labs, fostering collaborative team dynamics, and pioneering the integration of digital pathology and digital innovation in laboratory medicine.

His ultimate goal is simple: to improve patient care, making the pathology service the provider, employer, and investment of choice. Together with a dedicated team, we can achieve this vision and create a healthcare landscape that truly puts patients first.

The May Digital Pathology Roundup with Imogen Fitt of Signify Research is here.

We cover 3 main topics this month:
1. Updates and new releases in the scanner sector, Including 3DHISTECH
2. Cloud and Ai marketplace developments including Aiforia
3. The state of AI adoption and real-world implementations, with news from Ibex and Aiforia

We also clarify some news from last month. PathAI in its entirety isn't being sold off to Quest. Quest will be acquiring 'select assets of PathAI Diagnostics', which will evolve into Quest's 'AI and digital R&D and solutions center'.

Imogen joined Signify Research in 2018 as part of the Healthcare IT team. During her tenure Imogen has completed studies on digital pathology, LabIT and the use of AI in drug development, expanding Signify Research’s diagnostics and life sciences business coverage.

Is it time for digital biomarkers? Our guest today is Torbjørn Furuseth of DoMore Diagnostics.

Predictive and prognostic algorithms may be the crown jewel of digital pathology, enhancing our value as pathologists to be the chief purveyor of this information in assisting doctors and patients.

We discuss the unmet need in oncology, particularly in colon cancer, to develop predictive and prognostic tools to guide therapy. We also explore the advantages of digital pathology over molecular tools and how these methodologies can be used together in some cases. What goes into the development and validation of such tools? Why might new and innovative CPT codes be necessary to encourage innovation in digital pathology? How do reimbursement challenges affect the innovation pipeline for digital pathology? And in the increasingly global marketplace, what considerations must we take into account to help patients across the world?

Torbjørn is the CEO and Co-Founder of DoMore Diagnostics, a leader in AI and deep learning precision diagnostics for digital pathology, focused on outcome prediction to personalize cancer treatment. He is a medical doctor with broad experience in life sciences and oncology. After practicing as a physician in radiology and sports medicine, he transitioned into business and management as a consultant at McKinsey & Company, where he served several pharma and healthcare clients. Following McKinsey, he has held multiple leadership positions in Norwegian life science companies and served as CFO at two immuno-oncology companies. Torbjørn’s vision is to play an important role in an important innovation.

We have a new feature on Digital pathology Today: a monthly recap of the biggest and latest industry developments with Imogen Fitt of Siginfy Research.

April was a huge month, and it seems the pace of innovation and new developments individual pathology is increasing at a breakneck speed.

This month's recap features updates on AI Co-development partnerships, FDA approvals, acquisitions as well as Imogen's thoughts on the recent USCAP meeting in Baltimore.

Imogen joined Signify Research in 2018 as part of the Healthcare IT team. During her tenure Imogen has completed studies on digital pathology, LabIT and the use of AI in drug development, expanding Signify Research’s diagnostics and life sciences business coverage.

In this episode we discuss the enterprise pathology platform and how it is so much more than image management. “It’s where work gets done and data lives,” according to Krishna Bala of Proscia. We discuss the components or steps involved in digital pathology workflow. How do we make it all seamless?
What is the appropriate level of pathologist involvement in the design and implementation of such systems? How can software engineers acquire domain expertise? What does integration mean and how can we incorporate exciting new AI tools into our daily practice? We discuss the benefits of an open platform and why our guest thinks this model will ultimately win out.
Krishna Bala is currently Sr. VP of Engineering at Proscia, a leading provider of digital and computational pathology solutions. In this role, he leads the development of Proscia's Concentriq enterprise pathology platform, which is used by leading life sciences organizations and top diagnostic laboratories. Krishna is an experienced healthcare technologist with more than 20 years of experience in software development, data engineering, and AI/Machine-Learning. He is also an entrepreneur with several successful exits including an IPO as CTO/Founder. Krishna has a Ph.D. in Electrical Engineering from Columbia University in New York.